Press "esc" to clear
Go to Advanced Search

Showing results

20712080 of 2527
  • Embargo expired:
    19-Feb-2014 5:00 PM EST

Article ID: 613973

Bevacizumab (Avastin) Fails to Improve Survival for Patients Newly Diagnosed with Glioblastoma

University of Maryland School of Medicine

Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report in the Feb. 20 issue of the New England Journal of Medicine.

Released:
19-Feb-2014 4:30 PM EST
EXPERT AVAILABLE
Open in New Tab
Add to Favorites

Article ID: 613909

City of Hope Researchers Develop Test to Assess Effect of More Than 1,500 Chemicals on Estrogen

City of Hope

A team of researchers at City of Hope has developed a screening assay that can quickly assess up to 1,536 compounds’ effect on estrogen activity in the body. The test can also evaluate whether chemicals act as inhibitors of aromatase, an enzyme linked to breast cancer that converts androgen to estrogen.

Released:
18-Feb-2014 10:45 AM EST
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
valdarweb1copy.jpg

Article ID: 613753

The Genetics of Drug Tolerance

University of North Carolina Health Care System

If you're a doctor, choosing the best drug for a patient with schizophrenia isn't easy. Researchers at UNC School of Medicine are trying to help by better understanding the genetic underpinnings of drug side effects while creating a better way for geneticists to design experiments.

Released:
13-Feb-2014 8:00 AM EST
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 613376

MMIS, Inc. Develops Free Validation Solution to Help Life Science Companies Meet the OPEN PAYMENTS Federal Reports March 31st Deadline

MMIS-Inc.

MMIS, a leading provider of SaaS compliance solutions for the life science industry, introduces MediSpend® Validate, an easy-to-use, self-service tool, designed to help pharmaceutical and medical device companies validate all three Federal Open Payment Reports. MediSpend® Validate fills the gap in the current transparency process.

Released:
5-Feb-2014 3:00 PM EST
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 613254

Stopping Liver Failure From Painkiller Overdose

University of Adelaide

University of Adelaide researchers have identified a key step for the future prevention of liver failure resulting from taking too much of the everyday painkiller acetaminophen (also known as paracetamol).

Released:
4-Feb-2014 2:05 AM EST
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
  • Embargo expired:
    3-Feb-2014 12:05 AM EST

Article ID: 613187

Experts Issue "Blueprint for Action" to Combat Shortages of Life-Saving Drugs

Johns Hopkins Berman Institute of Bioethics

A group of prominent healthcare experts including bioethicists, pharmacists, policymakers and cancer specialists have proposed concrete steps for preventing and managing a nightmare scenario that is becoming all too common: shortages of life-saving drugs.

Released:
1-Feb-2014 4:00 PM EST
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
khan_omar.jpg

Article ID: 613084

FDA Approves New MS Treatment Regimen Developed at Wayne State University

Wayne State University Division of Research

Global research overseen by and conducted at the Wayne State University School of Medicine will immediately change the treatment regimen of millions of multiple sclerosis patients around the world.

Released:
30-Jan-2014 12:00 PM EST
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 613007

Altheus Therapeutics Announces the USPTO Has Awarded the Zoenasa Patent for Oral Combination Therapy

Altheus Therapeutics

/PRNewswire/ -- Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine). Combination therapy patents are uncommon and under-appreciated in the pharmaceutical industry because the Patent Office requires surprising, unexpected, or synergistic benefits from combining active ingredients into a single formulation. Altheus' success in procuring the strong and diverse patents for Zoenasa, including this most recent oral combination therapy patent, stems from rigorous studies demonstrating highly statistically significant synergy between Zoenasa's two components.

Released:
29-Jan-2014 11:00 AM EST
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Channels:

Pharmaceuticals

RichardLee.jpg

Article ID: 612880

Promising Class of Antibiotics Discovered for Treatment of Drug-Resistant Tuberculosis

St. Jude Children's Research Hospital

St. Jude Children’s Research Hospital scientists have discovered a promising new class of antibiotics that could aid efforts to overcome drug-resistance in tuberculosis, a global killer.

Released:
27-Jan-2014 1:00 PM EST
EXPERT AVAILABLE
Open in New Tab
Add to Favorites

Article ID: 612842

Moffitt Cancer Center Instrumental in FDA Approval of Revolutionary Two-Drug Combo to Treat Advanced Melanoma

Moffitt Cancer Center

Moffitt Cancer Center researchers have laid the groundwork for a revolutionary new combination therapy for the treatment of advanced melanoma – melanoma that cannot be removed surgically or has spread to other areas of the body. The newly FDA-approved therapy, Mekinist (trametinib) in combination with Tafinlar (dabrafenib), is one of the biggest advancements in melanoma treatment in the past 30 years.

Released:
27-Jan-2014 8:00 AM EST
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Showing results

20712080 of 2527





Chat now!